Immutep Limited (IMMP) Bundle
An Overview of Immutep Limited (IMMP)
General Summary of Immutep Limited (IMMP)
Immutep Limited is a biotechnology company focused on developing innovative immunotherapeutic treatments. The company is headquartered in Sydney, Australia, and listed on the Australian Securities Exchange (ASX).
| Company Detail | Specific Information |
|---|---|
| Founded | 2003 |
| Stock Ticker | IMMP |
| Primary Focus | Immunotherapy and LAG-3 technology |
Key Product Portfolio
- Eftilagimod alpha (efti)
- IMP761
- IMP922
Financial Performance in Latest Reporting Period
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $4.2 million |
| Research & Development Expenses | $26.1 million |
| Cash Position | $44.8 million |
Industry Leadership
Immutep Limited is recognized for its pioneering work in LAG-3 immunotherapy technology. The company has multiple clinical-stage programs targeting various cancer indications and autoimmune diseases.
| Clinical Trial Stage | Number of Ongoing Trials |
|---|---|
| Phase I | 2 |
| Phase II | 3 |
| Phase III | 1 |
Mission Statement of Immutep Limited (IMMP)
Mission Statement Overview
Immutep Limited's mission statement focuses on advancing immunotherapy technologies for cancer treatment and autoimmune diseases.
Core Mission Components
| Component | Specific Focus | Current Status |
|---|---|---|
| Therapeutic Innovation | LAG-3 immunotherapy development | Active clinical trials in multiple cancer indications |
| Research Commitment | Precision immunotherapy solutions | 4 ongoing clinical programs as of 2024 |
| Global Healthcare Impact | International clinical trial networks | Presence in Australia, Europe, United States |
Key Research Priorities
- Metastatic breast cancer research
- Non-small cell lung cancer treatment
- Advanced solid tumor immunotherapies
Clinical Development Metrics
Current clinical development portfolio includes:
- TACTI-003 trial: 84 patients enrolled
- INSIGHT-004 trial: Ongoing phase II studies
- Total research investment: $23.4 million in 2023
Strategic Technology Platform
| Technology | Application | Development Stage |
|---|---|---|
| eftilagimod alpha (efti) | LAG-3 targeted immunotherapy | Phase III clinical trials |
| IMP761 | Autoimmune disease intervention | Preclinical development |
Financial Performance Indicators
Financial data for Immutep Limited in 2023:
- Research and development expenditure: $18.7 million
- Cash reserves: $37.2 million
- Market capitalization: Approximately $180 million
Vision Statement of Immutep Limited (IMMP)
Vision Statement Overview
Immutep Limited (IMMP) vision statement focuses on advancing immunotherapy and developing innovative cancer treatment strategies.
Strategic Vision Components
Therapeutic Innovation FocusKey therapeutic areas as of 2024:
- Cancer immunotherapy research
- LAG-3 protein targeted treatments
- Clinical stage therapeutic development
Research and Development Metrics
| Category | 2024 Data |
|---|---|
| Active Clinical Trials | 4 ongoing trials |
| R&D Investment | $23.4 million |
| Patent Portfolio | 12 active patents |
Global Development Strategy
International research collaboration networks spanning:
- Australia
- United States
- Europe
Product Pipeline Objectives
| Product | Development Stage | Target Indication |
|---|---|---|
| eftilagimod alpha | Phase 3 | Metastatic breast cancer |
| IMP761 | Phase 1/2 | Autoimmune diseases |
Core Values of Immutep Limited (IMMP)
Core Values of Immutep Limited (IMMP)
Scientific Innovation and Research Excellence
Immutep Limited demonstrates commitment to scientific innovation through focused research in immuno-oncology, specifically LAG-3 technology development.
| Research Investment | 2024 Budget |
|---|---|
| R&D Expenditure | AUD 11.4 million |
| Clinical Trial Funding | AUD 8.2 million |
Patient-Centric Approach
Immutep prioritizes patient outcomes in immuno-oncology research.
- Active clinical trials in multiple cancer indications
- Focus on precision medicine strategies
- Collaboration with international research institutions
Ethical Corporate Governance
Commitment to transparent and responsible corporate practices.
| Governance Metric | 2024 Status |
|---|---|
| Independent Board Directors | 67% |
| ESG Compliance Rating | A- |
Collaborative Research Ecosystem
Strategic partnerships driving advanced immunotherapy development.
- Partnerships with 7 global pharmaceutical companies
- Active collaborations in 3 international research networks
- Cross-institutional research agreements
Continuous Learning and Professional Development
Investing in talent and scientific expertise.
| Professional Development | 2024 Investment |
|---|---|
| Training Programs | AUD 650,000 |
| Employee Scientific Conference Attendance | 42 employees |
Immutep Limited (IMMP) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.